Our data suggest that CM101-like compounds that covalently modify REL to inhibit its DNA-binding activity represent a promising approach for the treatment of cancers (especially B-cell lymphomas) whose survival depends on active nuclear REL. The gene discussed is REL; the disease is B-cell non-Hodgkin lymphoma.